|
FY2026
12 months to Apr 24, 2026
|
FY2025
12 months to Apr 25, 2025
|
FY2024
12 months to Apr 26, 2024
|
FY2023
12 months to Apr 28, 2023
|
FY2022
12 months to Apr 29, 2022
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Costs and expenses: | |||||
| Cost of products sold, excluding amortization of intangible assets | |||||
| Research and development expense | |||||
| Selling, general, and administrative expense | |||||
| Amortization of intangible assets | |||||
| Restructuring charges, net | |||||
| Certain litigation charges, net | |||||
| Other operating expense (income), net | |||||
| Operating profit | |||||
| Other non-operating expense (income), net | |||||
| Interest expense, net | |||||
| Income before income taxes | |||||
| Income tax provision | |||||
| Net income | |||||
| Net income attributable to noncontrolling interests | |||||
| Net income attributable to Medtronic | |||||
| Basic earnings per share (in dollars per share) | |||||
| Diluted earnings per share (in dollars per share) | |||||
| Basic weighted average shares outstanding (in shares) | |||||
| Diluted weighted average shares outstanding (in shares) |
Loading...
